Transcutaneous Electrical Acustimulation on Postoperative Bowel Function Recovery in Elderly Patients
2026년 8월 12일 업데이트: Xin Yu, Sir Run Run Shaw Hospital
Efficacy of Transcutaneous Electrical Acustimulation on Postoperative Bowel Function Recovery in Elderly Patients With Colorectal Cancer: A Multicenter Randomized Controlled Trial Study Protocol
The goal of this clinical trial is to clarify the efficacy and safety of transcutaneous electrical acustimulation (TEA) in elderly patients with colorectal cancer, and to evaluate its clinical value in promoting postoperative intestinal function recovery and reducing the incidence of intestinal complications. The main questions it aims to answer are:
Can TEA promote the recovery of intestinal function in elderly patients with colon cancer after surgery? What medical problems might occur to the participants when using TEA? The researchers will compare TEA with the control group (non-acupoint sham stimulation) to see if TEA is effective in promoting the recovery of intestinal function after surgery.
Participants will:
Starting from the first day after the surgery, they received TEA or sham stimulation twice a day for a total of 3 days.
Record the time of the first defecation, defecation, and eating. Record their symptoms and adverse events.
연구 개요
연구 유형
중재적
등록 (추정된)
190
단계
- 해당 없음
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 연락처
- 이름: Xin Yu
- 전화번호: 86006663
- 이메일: xinxin_yu@zju.edu.cn
연구 장소
-
-
Shandong
-
Binzhou, Shandong, 중국
- 아직 모집하지 않음
- Shandong Medical and Pharmaceutical University Hospital
-
연락하다:
- Shuhui Zhang
- 전화번호: 18354017338
- 이메일: 3259998310@qq.com
-
-
Zhejiang
-
Hangzhou, Zhejiang, 중국
- 모병
- Sir Run Run Shaw Hospital
-
연락하다:
- Xin Yu
- 전화번호: 86006663
- 이메일: xinxin_yu@zju.edu.cn
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
- 고령자
건강한 자원 봉사자를 받아들입니다
아니
설명
Inclusion Criteria:
- Age ≥ 65 years old.
- Elective minimally invasive (laparoscopic or robotic) resection of colorectal cancer.
- American Society of Anesthesiologists classification (ASA) 1-4.
- Able to understand the research process and the use of various assessment scales, and able to communicate effectively with the researchers.
- The patient voluntarily participates in this study and signs the informed consent form.
Exclusion Criteria:
- Previous history of abdominal gastrointestinal surgery.
- Planned for palliative or emergency surgery.
- Planned for open abdominal surgery or creation of a new stoma.
- Transfer to ICU.
- Diagnosed with severe heart, liver, kidney or mental system diseases.
- Patients with implanted cardiac pacemakers.
- Patients currently using or having used in the past month glucagon-like peptide-1 (GLP-1) receptor agonists, dual glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors.
- Planned to use epidural anesthesia or epidural analgesia.
- Presence of local skin lesions, infection at the stimulation site, or obvious skin allergy or severe skin sensitivity to electrodes/adhesive materials.
- Participated in other clinical studies within the past 3 months or received acupuncture treatment within the past month.
- Other conditions that the investigator considers make the patient unsuitable for participation in this study.
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: TEA
|
The subjects in the TEA group were placed in the supine position and received transcutaneous electrical acupoint stimulation at the bilateral PC6 and bilateral ST36 .
After confirming the location of the acupoints , special skin treatment was carried out.
The stimulation parameters for PC6 were set as follows: 0.1 seconds of opening stimulation, 0.4 seconds of closing stimulation, pulse width of 0.5 ms, pulse frequency of 100 Hz, and amplitude ranging from 1 to 10 mA (based on the maximum level that the subject could tolerate).
The stimulation parameters for ST36 were set as follows: 2 seconds of opening stimulation, 3 seconds of closing stimulation, pulse width of 0.5 ms, pulse frequency of 25 Hz, and amplitude ranging from 2 to 10 mA (based on the maximum level that the subject could tolerate).
|
|
가짜 비교기: sham-TEA
|
Sham-TEA was the same except that non-acupoints were used to replace ST36 and PC6.
The sham-acupoint for PC6 was located at about 15-20 cm away from PC6 (up to the elbow and outside of the coastal margin of the forearm not on any meridian) and the sham-point for ST36 was located at 10-15 cm down from and to the lateral side of ST36 not on any meridian
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Time to First Flatus
기간: Assessed up to 10 days after surgery
|
Defined as the period from the end of the surgery to the time of first flatus (hours).
|
Assessed up to 10 days after surgery
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Prolonged post operative ileus (PPOI)
기간: Assessed up to 72 hours after surgery
|
defined as no flatus for more than 72 hours
|
Assessed up to 72 hours after surgery
|
|
time to first defecation
기간: Assessed up to 10 days after surgery
|
Defined as the period from the end of the surgery to the time of first defecation (hours).
|
Assessed up to 10 days after surgery
|
|
time to first water intake
기간: Assessed up to 10 days after surgery
|
The time from the end of the surgery to the first water intake (hours)
|
Assessed up to 10 days after surgery
|
|
Time to tolerance of liquid diet
기간: Assessed up to 10 days after surgery
|
"Tolerance" is defined as no significant nausea or vomiting (PONV ≤ 4 points) within 4 hours after the liquid diet.
Record the time (in hours) from the end of the surgery to the first tolerance to the liquid diet.
|
Assessed up to 10 days after surgery
|
|
Time to tolerance of semi-liquid diet
기간: Assessed up to 10 days after surgery
|
"Tolerance" is defined as no significant nausea or vomiting (PONV ≤ 4 points) within 4 hours after semi-liquid food.
Record the time ( hours) from the end of the surgery to the first tolerance of semi-liquid food.
|
Assessed up to 10 days after surgery
|
|
Time to tolerance of solid food
기간: Assessed up to 10 days after surgery
|
"Tolerance" is defined as no significant nausea or vomiting (PONV ≤ 4 points) within 4 hours after solid food.
Record the time (hours) from the end of the surgery to the first tolerance of solid food.
|
Assessed up to 10 days after surgery
|
|
Time to first ambulation
기간: Assessed up to 10 days after surgery
|
The time from the end of the surgery to the first ambulation (hours).
|
Assessed up to 10 days after surgery
|
|
Postoperative nausea
기간: At 24, 48, and 72 hours after surgery
|
The number and frequency of postoperative nausea episodes
|
At 24, 48, and 72 hours after surgery
|
|
postoperative vomiting
기간: At 24, 48, and 72 hours after surgery
|
The number and frequency of postoperative vomiting
|
At 24, 48, and 72 hours after surgery
|
|
postoperative abdominal distension
기간: At 24, 48, and 72 hours after surgery
|
The number and frequency of postoperative abdominal distension
|
At 24, 48, and 72 hours after surgery
|
|
Use of anti-emetic drugs after surgery
기간: At 24, 48, and 72 hours after surgery
|
Number of participants using antiemetic drugs
|
At 24, 48, and 72 hours after surgery
|
|
Severity of postoperative pain
기간: At 24, 48, and 72 hours after surgery
|
The assessment was conducted using a numerical rating scale (NRS).
The scoring range was 0-10 (0 indicated no pain, while 10 indicated unbearable severe pain.
Scores of 1-3 indicated mild pain that could be tolerated; 4-6 indicated pain that affected sleep but was still tolerable; 7-10 indicated severe pain that affected appetite and sleep).
|
At 24, 48, and 72 hours after surgery
|
|
Use of opioids drugs after surgery
기간: At 24, 48, and 72 hours after surgery
|
The total dosage of all opioid analgesics used within 24 hours, 48 hours, and 72 hours after surgery, converted into morphine equivalents.
|
At 24, 48, and 72 hours after surgery
|
|
TEA Security
기간: Assessed up to 3 days after surgery
|
assessing the adverse events related to the equipment (including numbness in the hands, pain, and skin allergies)
|
Assessed up to 3 days after surgery
|
|
Postoperative complications
기간: From the time the patient signs the informed consent form until the end of the study follow-up (30 days after surgery)
|
The severity of complications was evaluated using the Clavien-Dindo classification system (grades I to V), with Clavien-Dindo grade ≥ III complications serving as the major surgical complications.
|
From the time the patient signs the informed consent form until the end of the study follow-up (30 days after surgery)
|
|
Total length of hospital stay
기간: Assessed up to 30 days after surgery
|
primary admission plus any readmission up to 30 days
|
Assessed up to 30 days after surgery
|
|
Unplanned readmission
기간: Assessed up to 30 days after surgery
|
Record the number of unplanned re-admissions within 30 days of hospital discharge
|
Assessed up to 30 days after surgery
|
|
Postoperative quality of recovery
기간: baseline and postoperative day 1 to day 7 (or until discharge, whichever comes first)
|
Assessed using the Quality of Recovery - 15 score (QoR-15) questionnaire preoperatively and daily.
The total score ranges from 0 to 150 points.
The higher the score, the better the post-anesthesia recovery quality.
|
baseline and postoperative day 1 to day 7 (or until discharge, whichever comes first)
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (실제)
2026년 6월 14일
기본 완료 (추정된)
2027년 4월 30일
연구 완료 (추정된)
2028년 5월 31일
연구 등록 날짜
최초 제출
2026년 4월 30일
QC 기준을 충족하는 최초 제출
2026년 4월 30일
처음 게시됨 (실제)
2026년 5월 8일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2026년 8월 14일
QC 기준을 충족하는 마지막 업데이트 제출
2026년 8월 12일
마지막으로 확인됨
2026년 8월 1일
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .